HOME > Company > Profile

Corprate Profile

Company GeneFrontier Corporation
Established October 13, 2010
Capital 10 million yen
Board of Directors
CEO Masaru Mitsuda
COO Takashi Ebihara
Director Takahisa Nakai
Auditor Katsuhiro Shiota
Shareholders KANEKA Corporation
Business 1. Providing innovative research products, services and technologies in protein engineering and drug discovery.
- Customized Human Monoclonal Antibody Generation service, partnered with AbD Serotec, a division of MorphoSys AG (Munich, Germany).
- PUREfrex®, reconstituted cell-free protein synthesis system.
- PUREfrex®RD, ribosome display utilizing PUREfrex®.
- Scaffold, an antibody alternative.

2. Development of Monoclonal Antibody Therapeutics.
Contact Todai-Kashiwa Venture Plaza Rm#308 5-4-19, Kashiwa-no-Ha, Kashiwa, Chiba 277-0882, JAPAN
Phone: +81-4-7137-6301
Facsimile: +81-4-7132-7530
E-mail: please contact here
"PUREfrex® is Registered in U.S. Patent and Trademark Office"